Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Bausch Health Americas, Inc.
The study will examine the safety and effectiveness of AMG 827 for the treatment of psoriatic arthritis. Patients will randomly receive either AMG 827 or placebo (a look-a-like liquid that does not have any drug in it) and neither the doctor nor the patient will know what treatment is being given.
Age
18–75
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Subject has had a diagnosis of psoriatic arthritis (by the Classification of Psoriatic Arthritis (CASPAR) criteria) for at least 6 months
Subject has ≥ 3 tender and ≥ 3 swollen joints
You may not be if
Subject has an active infection or history of infections (systemic anti-infectives were used within 28 days; requiring hospitalization or intravenous anti-infectives within 8 weeks; recurrent or chronic)
Significant concurrent medical conditions
Pregnant or breast feeding
Significant Laboratory abnormalities
Use of sulfasalazine, hydroxychloroquine, systemically administered calcineurin inhibitors, azathioprine, parenteral corticosteroids including intramuscular or intraarticular administration, or live vaccines within 28 days
Use of anti-TNF therapy within 2 months
Use of an anti-interleukin (IL)12/IL-23 drug or other experimental or commercially available biologic therapies for psoriasis and/or psoriatic arthritis within 3 months
Prior use of rituximab
Prior use of anti-IL-17 biologic therapy, including AMG 827
Clareo Health | AMG 827 in Subjects With Psoriatic Arthritis
